Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study. [electronic resource]
Producer: 20170804Description: 881-888 p. digitalISSN:- 1399-3062
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Allografts -- drug effects
- B-Lymphocytes -- drug effects
- Epstein-Barr Virus Infections -- blood
- Female
- Follow-Up Studies
- Graft Rejection -- epidemiology
- Herpesvirus 4, Human -- drug effects
- Humans
- Immunologic Factors -- administration & dosage
- Kidney Transplantation -- adverse effects
- Lymphoproliferative Disorders -- etiology
- Male
- Middle Aged
- Pilot Projects
- Retrospective Studies
- Rituximab -- administration & dosage
- Serologic Tests
- Tissue Donors
- Transplant Recipients
- Transplantation Conditioning -- methods
- Viremia -- prevention & control
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.